KDM6B and leukemia: These results indicate that GATA2 and MEIS1 are crucial downstream factors of leukemogenicity associated with ASXL1 truncating mutation that can be targeted either directly or indirectly via KDM6B inhibition to improve HSPC function and prevent leukemia transformation.